Helsinki-based Onego Bio has announced a significant funding boost of €14 million from the European Innovation Council (EIC) Accelerator Program and additional Series A investors. This new funding round brings Onego’s total capital raised in 2024 to €50.5M, elevating their overall funding to €65M. Specializing in producing Bioalbumen®, a bio-identical egg protein, Onego aims to reduce the environmental impact of traditional egg production by approximately 90%. The latest funds will accelerate their commercialization efforts in North America and Europe, including navigating the regulatory approval processes with the FDA and EFSA.
Manufactured as an industrial food ingredient, Onego’s Bioalbumen® offers bio-identical egg protein with a stable supply, full functionality, perfect protein quality, and neutral flavor, while having the potential to alleviate the environmental burden by ~90 %.
As a US-Finnish company, Onego is moving at full speed in commercializing in North America, where the regulatory landscape allows a faster market entry. The company is on track to submit a Generally Recognized as Safe (GRAS) notice to the FDA this year, with hope of receiving a “no questions” letter from the FDA in 2025. The newly gained EIC funding will fuel the company’s go-to-market plan also in the EU, including securing regulatory approval from the European Food Safety Authority (EFSA).
Maija Itkonen, CEO & co-founder of Onego Bio said: “The new funding and immense support from our investors demonstrates their confidence in our vision and the potential of innovations like Bioalbumen® to build a more sustainable system. It also shows that the EU recognizes precision fermentation as a solution to address sustainability issues and enhance food security in Europe and worldwide. However, to remain competitive and fully capture the potential of exceptional European research and innovation, the regulatory approval process must be accelerated, as the EU currently lags behind other regions in this area.”
Onego Bio was selected for EIC funding from a highly competitive pool of 969 applicants, of which 347 companies were interviewed by juries of experienced investors and entrepreneurs, with only the top 68 receiving funding. EIC Accelerator selects only startups or SMEs with a high-impact product, service, or business model that demonstrate the potential to scale-up and create new markets or disrupt existing ones in Europe and even worldwide. In the 2024 work program, EIC identified precision fermentation as an area where breakthrough technologies or game-changing innovations can have a major impact to improve the sustainability, efficiency, and resilience of the European food supply chain through decoupling food production from the soil and minimizing environmental impacts including water pollution.
Founded in 2022 as a spinoff from VTT (Technical Research Center of Finland), Onego is already working with major food companies on product formulation in a wide range of products, from baked goods, confectionery, snacks, sauces, pasta, meat alternatives, and more. With commercial operations in San Diego, California, the company is currently producing Bioalbumen® with co-manufacturers while finalizing plans for its first own manufacturing unit. Onego employs a patented fungal fermentation technology that is highly productive and scalable, demonstrating industrial production potential and enabling competitive pricing compared to conventional egg production methods. A single Onego full-scale manufacturing unit will boast a two-million-liter fermentation capacity, effectively delivering the protein equivalent produced by six million laying hens.
Click to read more funding news.
Read the orginal article: https://arcticstartup.com/onego-bio-raises-e14m/
